See reviews, salaries & interviews from MannKind Corporation employees in Danbury, CT. Sign In Explore Jobs Companies Salaries Careers For Employers Post a Job Jobs Discover Jobs Companies Discover Companies Compare Companies Write a Review Salaries Discover Salaries He was the devoted husband of the late Gladys (Farrah) St. Pierre. Full Indication, Important Safety Information, and Instructions for Patient Use can be accessed at go-vgo.com. MannKind Corporation was named after its founder, Alfred E. Mann . Danbury, CT 06810. . 18d. Danbury, CT Size: 201 to 500 Employees Founded: 1991 Type: Company - Public (MNKD) Industry: Biotech & Pharmaceuticals Revenue: $100 to $500 million (USD) Returns the exact phrase match within quotes. Address 1 Casper St Danbury, CT 06810 United States of America Website mannkindcorp.com Tel 203-798-8000 Company Status Public MannKind Corporation focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. WESTLAKE VILLAGE, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today reported financial results for the fourth quarter and full year ended December 31, 2020. has been appointed to its Board of Directors, effectiveDecember 1, 2020. There are currently three active principals. MannKind Corporation is focused on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Search jobs. The notification was processed in accordance with the regulations of the FTZ Board ( 15 CFR part 400 ), including notice in the Federal Register inviting public comment . Full Prescribing Information can be accessed at tyvaso.com. Systems Engineer (4 - 6 Month Contract) Danbury, CT. $38.00 - $42.00 Per Hour (Glassdoor est.) . 1 Casper Street Danbury, CT 06810 30930 Russell Ranch Road Suite 300 Westlake Village, CA 91362 293 Boston Post Road West Suite 330 Marlborough, MA 01752 MannKind Corporation. $38 to $42 Hourly. Mannkind Corporation is located at 1 Casper St, Danbury, CT 06810. Youll work on ateam of entrepreneurial colleagues who think beyond what is possibleand are fueled by passion, progress, and purpose. This location is in Fairfield County and the Bridgeport-Stamford-Norwalk, CT Metropolitan Area. Senior Associate Manager, Accounting (Senior Accountant) MannKind Corporation 3.8. . See if you qualify! Company Description: MannKind is a biopharmaceutical company focusing on developing and commercializing therapeutic products to treat patients with endocrine and orphan lung diseases. Website: mannkindcorp.com. Manufacturing. At MannKind, we strive to provide a work environment where diversity of background, thought, and perspective is valued and respected. Its lead product, Afrezza, is an ultra rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. Systems Engineer (4 - 6 Month Contract) MannKind Corporation. MannKind Corporation. Privacy Policy View jobs MannKind Corporation Employee Reviews in Danbury, CT Review this company Job Title All Location Danbury, CT 21 reviews Ratings by category 3.7 Work-Life Balance 4.0 Pay & Benefits 2.8 Job Security & Advancement 3.3 Management 3.4 Culture Sort by Helpfulness Rating Date Language Address: 1 Casper St Danbury CT 06810-6903: Issue Date: 2014-08-15 : Effective Date: 2021-07-01 : Expiration Date: 2022-06-30 : Other licenses. "Customer Service Manager""Customer Service Supervisor" retrieves an opportunity for a Customer Service Manager or a Customer Service Supervisor. Patent Notices Check out our research and development pipeline focused on endocrine and orphan lung diseases. Corporate Governance. 10 Q&A Interviews Photos Want to work here? One Casper Street Danbury, CT 06810 Phone: 203-789-3403 Website: http://www.mannkindcorp.com/ General Information: MannKind Corporation is a biopharmaceutical company focused on the discovery and development of therapeutic products for diseases such as diabetes. MannKind Corporation Engaged Employer Overview 74 Reviews 22 Jobs 91 Salaries 8 Interviews 44 Benefits 24 Photos 16 Diversity + Add a Review MannKind Corporation Reviews Updated May 1, 2023 Filter by Topic Work Life Balance Coworkers Senior Leadership Culture Compensation Management Benefits Career Development Workplace Diversity & Inclusion Roger was born on June 15, 1936 in Lawrence, Massachusetts. Learn about MannKind Corporation Danbury, CT office. Edit the information displayed in this box. Report Job. On January 6, 2023, MannKind Corporation submitted a notification of proposed production activity to the FTZ Board for its facility within Subzone 76B, in Danbury, Connecticut. At MannKind our employees are our number one asset, and we continue to be a tight-knit community where each of us has a critical role in our success. What? The license effective date is July 1, 2021. All rights reserved. Phone: (203) 798-8000 . At MannKind, we are committed to developing and commercializing innovative therapeutic products and devices for people living with endocrine and orphan lung diseases. life more humann.SM. Check MannKind Corporation in Danbury, CT, Casper Street on Cylex and find (203) 798-8., contact info, opening hours.. Sign in; Register. MannKind Corporation. MannKind Corporation. Credential Code Credential Type We are in pursuit of a world where people with serious medical conditions can live life more humann. Easy 1-Click Apply (MANNKIND CORPORATION) Associate I, Manufacturing Operations (Saturday/Days) job in Danbury, CT. View job description, responsibilities and qualifications. MannKind Corporation 20 years Executive VP Technical Operations, 2010 - Present13 years Danbury, CT Reporting to CEO and COO, oversee all technical aspects of company, leading diverse 50-. Manager + Accounting returns opportunities for Manager and Accounting. United Therapeutics Tyvaso DPI represents the second FDA-approved product utilizing MannKinds innovative Technosphere inhalation technology. Associate Scientist, Quality Control (Chemistry) (Tues-Sat, 12:30pm to 9pm) Danbury, CT. He was the son of the late Harvey St. Pierre and Annette Bibeau St. Pierre. Committed to diversity, at MannKind we depend on a rich blend of ideas . Address: 1 Casper St, Danbury, CT 06810. Industry. Full Prescribing Information, including BOXED WARNING, Instructions for Use, and Medication Guide can be accessed at afrezza.com. Easy Apply. Terms of Use Report Job. {"links":{"self":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/News","first":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/News?page=1","next":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/News?page=2","prev":null,"last":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/News?page=5"},"meta":{"executionDate":"2023-06-03T14:18:04","cmsDomain":"http://investors.mannkindcorp.com","count":100},"data":[{"id":19066,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/19066","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/dr-burkhard-blank-joins-mannkind-executive-vice-president"},"title":"Dr. Burkhard Blank Joins MannKind as Executive Vice President of Research & Development and Chief Medical Officer","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. , May 24, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced Burkhard Blank , MD, has joined the company","language":"en","releaseDate":{"dateUTC":"2023-05-24T12:30:00","date":"2023-05-24T08:30:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Dr. Burkhard Blank Joins MannKind as Executive Vice President of Research & Development and Chief Medical Officer","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/19066/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-05-24T12:30:43","lastUpdatedUTC":"2023-05-24T12:30:43"},{"id":18991,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18991","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participate-2023-rbc-capital-markets-global"},"title":"MannKind Corporation to Participate in the 2023 RBC Capital Markets Global Healthcare Conference","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. and WESTLAKE VILLAGE, Calif. , May 10, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that its","language":"en","releaseDate":{"dateUTC":"2023-05-10T10:00:00","date":"2023-05-10T06:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Participate in the 2023 RBC Capital Markets Global Healthcare Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18991/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-05-10T10:00:38","lastUpdatedUTC":"2023-05-10T10:00:38"},{"id":18986,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18986","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/correction-mannkind-corporation-reports-2023-first-quarter"},"title":"CORRECTION -- MannKind Corporation Reports 2023 First Quarter Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 5:00 p.m. (ET) DANBURY, Conn. and WESTLAKE VILLAGE, Calif. , May 09, 2023 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today byMannKind Corporation(Nasdaq: MKND), please note in the second table, titled \"CONDENSED CONSOLIDATED BALANCE","language":"en","releaseDate":{"dateUTC":"2023-05-10T00:21:00","date":"2023-05-09T20:21:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"CORRECTION -- MannKind Corporation Reports 2023 First Quarter Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18986/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-05-10T00:22:09","lastUpdatedUTC":"2023-05-10T00:22:09"},{"id":18956,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18956","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2023-first-quarter-financial"},"title":"Mannkind Corporation Reports 2023 First Quarter Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 5:00 p.m. (ET) 1Q 2023 Total Revenues of $41 million ; +239% vs. 1Q 2022 1Q 2023 Revenues associated with Tyvaso DPI of $23 million 1Q 2023 Loss from operations decreased 72% vs. 1Q 2022 to $6 million $167 million of Cash, Cash Equivalents and Investments at","language":"en","releaseDate":{"dateUTC":"2023-05-09T20:00:00","date":"2023-05-09T16:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Mannkind Corporation Reports 2023 First Quarter Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18956/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-05-09T20:00:25","lastUpdatedUTC":"2023-05-09T20:00:25"},{"id":18926,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18926","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-hold-2023-first-quarter-financial-results"},"title":"MannKind Corporation to Hold 2023 First Quarter Financial Results Conference Call on May 9, 2023","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. and WESTLAKE VILLAGE, Calif. , May 02, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2023 first quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on","language":"en","releaseDate":{"dateUTC":"2023-05-02T21:00:00","date":"2023-05-02T17:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Hold 2023 First Quarter Financial Results Conference Call on May 9, 2023","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18926/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-05-02T21:00:21","lastUpdatedUTC":"2023-05-02T21:00:21"},{"id":18846,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18846","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/lauren-sabella-joins-mannkind-executive-vice-president-chief"},"title":"Lauren Sabella Joins Mannkind as Executive Vice President, Chief Operating Officer","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. , March 27, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced Lauren Sabella has joined the company as","language":"en","releaseDate":{"dateUTC":"2023-03-27T20:05:00","date":"2023-03-27T16:05:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Lauren Sabella Joins Mannkind as Executive Vice President, Chief Operating Officer","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18846/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-03-27T20:05:54","lastUpdatedUTC":"2023-03-27T20:05:54"},{"id":18836,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18836","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participate-oppenheimer-33rd-annual"},"title":"MannKind Corporation to Participate in Oppenheimer 33rd Annual Healthcare Conference","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. and WESTLAKE VILLAGE, Calif. , March 07, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that","language":"en","releaseDate":{"dateUTC":"2023-03-07T22:00:00","date":"2023-03-07T17:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Participate in Oppenheimer 33rd Annual Healthcare Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18836/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-03-07T22:00:21","lastUpdatedUTC":"2023-03-07T22:00:21"},{"id":18811,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18811","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2022-fourth-quarter-and-full-year"},"title":"MannKind Corporation Reports 2022 Fourth Quarter and Full Year Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 5:00 p.m. (ET) 2022 Total Revenues of $100 million ; +32% vs. 2021 2022 Royalties from Tyvaso DPI of $16 million ; 4Q 2022 of $9 million 4Q 2022 Commercial Products Net Revenue of $17 million ;+54% vs. 4Q 2021 $173 million of Cash and Cash Equivalents and","language":"en","releaseDate":{"dateUTC":"2023-02-23T21:00:00","date":"2023-02-23T16:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2022 Fourth Quarter and Full Year Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18811/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-02-23T21:00:27","lastUpdatedUTC":"2023-02-23T21:00:27"},{"id":18796,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18796","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-give-oral-presentation-meal-challenge-results-afrezzar"},"title":"MannKind to Give Oral Presentation on Meal Challenge Results From the Afrezza With Basal Combination (ABC Study) at 16th Annual ATTD Conference","type":{"title":"General","id":3886},"teaser":"Inhaled Technosphere Insulin (TI) lowered peak glucose levels 30 minutes faster than injectable rapid-acting insulin delivered through an AID insulin pump and significantly lowered post-prandial glucose (PPG) from 45-120 minutes after a controlled meal challenge test MannKind is planning a larger","language":"en","releaseDate":{"dateUTC":"2023-02-22T11:05:00","date":"2023-02-22T06:05:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind to Give Oral Presentation on Meal Challenge Results From the Afrezza With Basal Combination (ABC Study) at 16th Annual ATTD Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18796/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-02-22T11:05:32","lastUpdatedUTC":"2023-02-22T11:05:32"},{"id":18791,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18791","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-hold-2022-fourth-quarter-and-full-year"},"title":"MannKind Corporation to Hold 2022 Fourth Quarter and Full Year Financial Results Conference Call on February 23, 2023","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. and WESTLAKE VILLAGE, Calif. , Feb. 16, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2022 fourth quarter and full year financial results and its management will host a conference call to discuss these results and corporate updates at 5:00 PM (Eastern","language":"en","releaseDate":{"dateUTC":"2023-02-16T22:00:00","date":"2023-02-16T17:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Hold 2022 Fourth Quarter and Full Year Financial Results Conference Call on February 23, 2023","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18791/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-02-16T22:00:20","lastUpdatedUTC":"2023-02-16T22:00:20"},{"id":18776,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18776","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participate-svb-securities-global-biopharma"},"title":"Mannkind Corporation to Participate in the SVB Securities Global Biopharma Conference","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. and WESTLAKE VILLAGE, Calif. , Feb. 10, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that its","language":"en","releaseDate":{"dateUTC":"2023-02-10T22:00:00","date":"2023-02-10T17:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Mannkind Corporation to Participate in the SVB Securities Global Biopharma Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18776/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-02-10T22:00:18","lastUpdatedUTC":"2023-02-10T22:00:18"},{"id":18746,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18746","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participate-lytham-partners-investor-select"},"title":"MannKind Corporation to Participate in the Lytham Partners Investor Select Conference","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. and WESTLAKE VILLAGE, Calif. , Jan. 24, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that its","language":"en","releaseDate":{"dateUTC":"2023-01-24T11:00:00","date":"2023-01-24T06:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Participate in the Lytham Partners Investor Select Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18746/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-01-24T11:00:27","lastUpdatedUTC":"2023-01-24T11:00:27"},{"id":18741,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18741","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkinds-inhaled-clofazimine-will-advance-adaptive-phase-23"},"title":"MannKinds Inhaled Clofazimine Will Advance to an Adaptive Phase 2/3 Study For Potential Treatment of Rare Lung Disease","type":{"title":"General","id":3886},"teaser":"Direct delivery of clofazimine to the lungs may provide a treatment option for nontuberculous mycobacterial (NTM) lung disease that potentially overcomes systemic toxicity and lessens side effects Paper published on clofazimine inhalation suspension demonstrates promising tolerability and","language":"en","releaseDate":{"dateUTC":"2023-01-23T11:05:00","date":"2023-01-23T06:05:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKinds Inhaled Clofazimine Will Advance to an Adaptive Phase 2/3 Study For Potential Treatment of Rare Lung Disease","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18741/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-01-23T11:07:16","lastUpdatedUTC":"2023-01-23T11:07:16"},{"id":18726,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18726","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-present-2023-annual-jp-morgan-healthcare"},"title":"MannKind Corporation to Present at 2023 Annual J.P. Morgan Healthcare Conference","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. and WESTLAKE VILLAGE, Calif. , Jan. 05, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) a company focused on the development and commercialization of innovative therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief","language":"en","releaseDate":{"dateUTC":"2023-01-05T11:00:00","date":"2023-01-05T06:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Present at 2023 Annual J.P. Morgan Healthcare Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18726/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2023-01-05T11:00:21","lastUpdatedUTC":"2023-01-05T11:00:21"},{"id":18716,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18716","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-present-two-posters-22nd-annual-diabetes-technology"},"title":"MannKind to Present Two Posters at 22nd Annual Diabetes Technology Meeting","type":{"title":"General","id":3886},"teaser":"Technosphere Insulin (TI) peaked 30 minutes faster and significantly reduced postprandial glucose excursions (PPGE) at 60 minutes compared to subcutaneous insulins The Afrezza with Basal Combination (ABC) Study demonstrated similar glucose control between the three treatment groups; data to be","language":"en","releaseDate":{"dateUTC":"2022-11-10T11:05:00","date":"2022-11-10T06:05:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind to Present Two Posters at 22nd Annual Diabetes Technology Meeting","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18716/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-11-10T11:09:28","lastUpdatedUTC":"2022-11-10T11:09:28"},{"id":18701,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18701","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2022-third-quarter-financial"},"title":"MannKind Corporation Reports 2022 Third Quarter Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 9:00 a.m. (ET) 3Q 2022 Total Revenues of $32.8 million ; +48% vs. 3Q 2021 3Q 2022 Royalties from Tyvaso DPI of $6.2 million 3Q 2022 Commercial Products Net Revenue of $16.3 million ; +67% vs. 3Q 2021 DANBURY, Conn. and WESTLAKE VILLAGE, Calif. , Nov.","language":"en","releaseDate":{"dateUTC":"2022-11-08T13:00:00","date":"2022-11-08T08:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2022 Third Quarter Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18701/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-11-08T13:00:55","lastUpdatedUTC":"2022-11-08T13:00:55"},{"id":18676,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18676","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-hold-2022-third-quarter-financial-results"},"title":"MannKind Corporation to Hold 2022 Third Quarter Financial Results Conference Call on November 8, 2022","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. and WESTLAKE VILLAGE, Calif. , Nov. 01, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2022 third quarter and year to date financial results and its management will host a conference call to discuss these results and corporate updates at 9:00 AM","language":"en","releaseDate":{"dateUTC":"2022-11-01T10:00:00","date":"2022-11-01T06:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Hold 2022 Third Quarter Financial Results Conference Call on November 8, 2022","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18676/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-11-01T10:00:41","lastUpdatedUTC":"2022-11-01T10:00:41"},{"id":18656,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18656","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participate-lytham-partners-fall-2022"},"title":"MannKind Corporation to Participate in the Lytham Partners Fall 2022 Investor Conference","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. and WESTLAKE VILLAGE, Calif. , Sept. 21, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of innovative therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief","language":"en","releaseDate":{"dateUTC":"2022-09-21T21:00:00","date":"2022-09-21T17:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Participate in the Lytham Partners Fall 2022 Investor Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18656/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-09-21T21:00:47","lastUpdatedUTC":"2022-09-21T21:00:47"},{"id":18646,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18646","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-successfully-completes-phase-1-study-inhaled"},"title":"Mannkind Successfully Completes Phase 1 Study of Inhaled Clofazimine","type":{"title":"General","id":3886},"teaser":"Study supports the dosing regimen that will be pursued in further clinical programs No serious adverse events or QT prolongation identified Planning underway to discuss results and the ongoing clinical program with the FDA DANBURY, Conn. and WESTLAKE VILLAGE, Calif. , Sept.","language":"en","releaseDate":{"dateUTC":"2022-09-06T10:15:00","date":"2022-09-06T06:15:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Mannkind Successfully Completes Phase 1 Study of Inhaled Clofazimine","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18646/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-09-06T10:15:24","lastUpdatedUTC":"2022-09-06T10:15:24"},{"id":18641,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18641","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participate-hc-wainwright-24th-annual"},"title":"MannKind Corporation to Participate in the H.C. Wainwright 24th Annual Global Investment Conference","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. and WESTLAKE VILLAGE, Calif. , Sept. 01, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of innovative therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief","language":"en","releaseDate":{"dateUTC":"2022-09-01T10:00:00","date":"2022-09-01T06:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Participate in the H.C. Wainwright 24th Annual Global Investment Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18641/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-09-01T10:00:16","lastUpdatedUTC":"2022-09-01T10:00:16"},{"id":18536,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18536","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2022-second-quarter-financial"},"title":"MannKind Corporation Reports 2022 Second Quarter Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 5:00 p.m. (ET) Tyvaso DPI approved by the FDA in May representing the second FDA-approved product using the Technosphere inhalation platform V-Go acquired May 31 ; $2.1 million Net Revenue recognized for June 2Q 2022 Commercial Products Net Revenue of $12.7","language":"en","releaseDate":{"dateUTC":"2022-08-09T20:00:00","date":"2022-08-09T16:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2022 Second Quarter Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18536/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-08-09T20:00:20","lastUpdatedUTC":"2022-08-09T20:00:20"},{"id":18516,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18516","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-hold-2022-second-quarter-financial-results"},"title":"MannKind Corporation to Hold 2022 Second Quarter Financial Results Conference Call on August 9, 2022","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. and WESTLAKE VILLAGE, Calif. , Aug. 02, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2022 second quarter and year to date financial results and its management will host a conference call to discuss these results and corporate updates at 5:00 PM","language":"en","releaseDate":{"dateUTC":"2022-08-02T10:00:00","date":"2022-08-02T06:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Hold 2022 Second Quarter Financial Results Conference Call on August 9, 2022","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18516/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-08-02T10:02:23","lastUpdatedUTC":"2022-08-02T10:02:23"},{"id":18491,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18491","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participate-btig-biotechnology-conference"},"title":"MannKind Corporation to Participate in the BTIG Biotechnology Conference","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. and WESTLAKE VILLAGE, Calif. , Aug. 01, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of innovative therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief","language":"en","releaseDate":{"dateUTC":"2022-08-01T10:00:00","date":"2022-08-01T06:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Participate in the BTIG Biotechnology Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18491/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-08-01T10:00:32","lastUpdatedUTC":"2022-08-01T10:00:32"},{"id":18486,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18486","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-host-product-theater-and-booth-american-diabetes"},"title":"Mannkind to Host Product Theater and Booth at the American Diabetes Associations 82nd Scientific Sessions in New Orleans, June 3-7","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , June 03, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of innovative therapeutic products for patients with endocrine and orphan lung diseases, will showcase its mealtime insulin solutions and","language":"en","releaseDate":{"dateUTC":"2022-06-03T14:00:00","date":"2022-06-03T10:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Mannkind to Host Product Theater and Booth at the American Diabetes Associations 82nd Scientific Sessions in New Orleans, June 3-7","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18486/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-06-03T14:00:15","lastUpdatedUTC":"2022-06-03T15:57:40"},{"id":18471,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18471","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkinds-technospherer-inhalation-platform-utilized-fda"},"title":"MannKinds Technosphere Inhalation Platform Utilized in FDA-Approved Tyvaso DPI","type":{"title":"General","id":3886},"teaser":"Tyvaso DPI represents the second FDA-approved product utilizing MannKinds Technosphere inhalation technology First approval of a dry powder inhaled treatment for PAH and PH-ILD Manufacturing of Tyvaso DPI for United Therapeutics underway at MannKinds Connecticut facility with product","language":"en","releaseDate":{"dateUTC":"2022-05-24T10:00:00","date":"2022-05-24T06:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKinds Technosphere Inhalation Platform Utilized in FDA-Approved Tyvaso DPI","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18471/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-05-24T10:00:25","lastUpdatedUTC":"2022-05-24T10:00:25"},{"id":18426,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18426","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-ring-nasdaq-stock-market-opening-bell"},"title":"MannKind Corporation to Ring the Nasdaq Stock Market Opening Bell","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. and DANBURY, Conn. , May 19, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief","language":"en","releaseDate":{"dateUTC":"2022-05-19T10:00:00","date":"2022-05-19T06:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Ring the Nasdaq Stock Market Opening Bell","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18426/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-05-19T10:00:20","lastUpdatedUTC":"2022-05-19T10:00:20"},{"id":18421,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18421","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-announces-agreement-acquire-v-gor-insulin"},"title":"MannKind Corporation Announces Agreement to Acquire V-Go Insulin Delivery Device From Zealand Pharma","type":{"title":"General","id":3886},"teaser":"The once-daily insulin delivery device strengthens MannKinds commitment to offering innovative mealtime diabetes solutions DANBURY, Conn. and WESTLAKE VILLAGE, Calif. , May 17, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization","language":"en","releaseDate":{"dateUTC":"2022-05-17T10:06:00","date":"2022-05-17T06:06:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Announces Agreement to Acquire V-Go Insulin Delivery Device From Zealand Pharma","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18421/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-05-17T10:06:18","lastUpdatedUTC":"2022-05-17T10:06:18"},{"id":18336,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18336","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participating-upcoming-conferences-2"},"title":"MannKind Corporation Participating at Upcoming Conferences","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. and DANBURY, Conn. , May 09, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that it will be","language":"en","releaseDate":{"dateUTC":"2022-05-09T10:00:00","date":"2022-05-09T06:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Participating at Upcoming Conferences","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18336/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-05-09T10:00:23","lastUpdatedUTC":"2022-05-09T10:00:23"},{"id":18316,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18316","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2022-first-quarter-financial"},"title":"MannKind Corporation Reports 2022 First Quarter Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 5:00 p.m. (ET) 1Q 2022 Afrezza Net Revenue of $9.8 million ; +21% vs. 1Q 2021 1Q 2022 Afrezza Gross Margin 77%; Gross Profit +99% vs 1Q 2021 $233.0 million of Cash, Cash Equivalents, and Investments at March 31, 2022 Tyvaso DPI PDUFA date May 2022 DANBURY, Conn.","language":"en","releaseDate":{"dateUTC":"2022-05-05T20:00:00","date":"2022-05-05T16:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2022 First Quarter Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18316/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-05-05T20:00:28","lastUpdatedUTC":"2022-05-05T20:00:28"},{"id":18301,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18301","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-hold-2022-first-quarter-financial-results"},"title":"MannKind Corporation to Hold 2022 First Quarter Financial Results Conference Call on May 5, 2022","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. and WESTLAKE VILLAGE, Calif. , April 28, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2022 first quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time)","language":"en","releaseDate":{"dateUTC":"2022-04-28T10:00:00","date":"2022-04-28T06:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Hold 2022 First Quarter Financial Results Conference Call on May 5, 2022","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18301/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-04-28T10:00:14","lastUpdatedUTC":"2022-04-28T10:00:14"},{"id":18296,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18296","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-presents-poster-15th-international-conference-advanced"},"title":"MannKind Presents Poster at 15th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2022) to Be Held April 27-30","type":{"title":"General","id":3886},"teaser":"Simplified 2x dose of Technosphere Insulin (TI) produced a statistically significant improvement in PPGE between Dose 1 & 2 from 45-120 minutes Higher dose of TI resulted in a mean difference of 52 mg/dL in PPGE at 120 minutes, with no new safety concerns WESTLAKE VILLAGE, Calif.","language":"en","releaseDate":{"dateUTC":"2022-04-27T10:05:00","date":"2022-04-27T06:05:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Presents Poster at 15th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2022) to Be Held April 27-30","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18296/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-04-27T10:05:24","lastUpdatedUTC":"2022-04-27T10:05:24"},{"id":18266,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18266","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/united-therapeutics-announces-publication-tyvaso-dpitm-breeze"},"title":"United Therapeutics Announces the Publication of Tyvaso DPI BREEZE Clinical and Long-term Data in the Journal Pulmonary Circulation","type":{"title":"General","id":3886},"teaser":null,"language":"en","releaseDate":{"dateUTC":"2022-04-06T10:00:00","date":"2022-04-06T06:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"external","link":{"id":null,"source":"url","title":"https://ir.unither.com/news/press-releases/press-release-details/2022/United-Therapeutics-Announces-the-Publication-of-Tyvaso-DPI-BREEZE-Clinical-and-Long-term-Data-in-the-Journal-Pulmonary-Circulation/default.aspx","url":"https://ir.unither.com/news/press-releases/press-release-details/2022/United-Therapeutics-Announces-the-Publication-of-Tyvaso-DPI-BREEZE-Clinical-and-Long-term-Data-in-the-Journal-Pulmonary-Circulation/default.aspx"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-04-06T19:39:08","lastUpdatedUTC":"2022-04-06T19:48:16"},{"id":18251,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18251","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participate-lytham-partners-spring-2022"},"title":"MannKind Corporation to Participate in the Lytham Partners Spring 2022 Investor Conference","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. , March 28, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael","language":"en","releaseDate":{"dateUTC":"2022-03-28T10:05:00","date":"2022-03-28T06:05:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Participate in the Lytham Partners Spring 2022 Investor Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18251/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-03-28T10:06:33","lastUpdatedUTC":"2022-03-28T10:06:33"},{"id":18236,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18236","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participate-cantor-virtual-rare-orphan"},"title":"MannKind Corporation to Participate in the Cantor Virtual Rare Orphan Disease Summit","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. , March 22, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Scientific Officer, Thomas","language":"en","releaseDate":{"dateUTC":"2022-03-22T10:05:00","date":"2022-03-22T06:05:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Participate in the Cantor Virtual Rare Orphan Disease Summit","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18236/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-03-22T10:06:25","lastUpdatedUTC":"2022-03-22T10:06:25"},{"id":18231,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18231","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participate-oppenheimer-32nd-annual"},"title":"MannKind Corporation to Participate in Oppenheimer 32nd Annual Healthcare Conference","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. , March 08, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael","language":"en","releaseDate":{"dateUTC":"2022-03-08T11:05:00","date":"2022-03-08T06:05:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Participate in Oppenheimer 32nd Annual Healthcare Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18231/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-03-08T11:06:26","lastUpdatedUTC":"2022-03-08T11:06:26"},{"id":18171,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18171","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2021-fourth-quarter-and-full-year"},"title":"MannKind Corporation Reports 2021 Fourth Quarter and Full Year Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 5:00 p.m. (ET) 2021 Total Revenues of $75.4 million ; +16% vs. 2020 4Q 2021 Afrezza Net Revenue of $11.3 million ; +13% vs. 4Q 2020 $260.7 million of Cash, Cash Equivalents and Investments at December 31, 2021 Commenced clofazimine Phase 1 clinical trial in 1Q","language":"en","releaseDate":{"dateUTC":"2022-02-24T21:00:00","date":"2022-02-24T16:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2021 Fourth Quarter and Full Year Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18171/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-02-24T21:02:28","lastUpdatedUTC":"2022-02-24T21:02:28"},{"id":18166,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18166","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/update-tyvaso-dpitm-new-drug-application"},"title":"Update on Tyvaso DPI New Drug Application","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. and DANBURY, Conn. , Feb. 24, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, was informed that the U.S.","language":"en","releaseDate":{"dateUTC":"2022-02-24T11:05:00","date":"2022-02-24T06:05:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Update on Tyvaso DPI New Drug Application","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18166/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-02-24T11:06:21","lastUpdatedUTC":"2022-02-24T11:06:21"},{"id":18151,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18151","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-hold-2021-fourth-quarter-and-full-year"},"title":"MannKind Corporation to Hold 2021 Fourth Quarter and Full Year Financial Results Conference Call on February 24, 2022","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. and WESTLAKE VILLAGE, Calif. , Feb. 21, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2021 fourth quarter and full year financial results, and its management will host a conference call to discuss the financial results and corporate updates at 5:00","language":"en","releaseDate":{"dateUTC":"2022-02-21T14:05:00","date":"2022-02-21T09:05:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Hold 2021 Fourth Quarter and Full Year Financial Results Conference Call on February 24, 2022","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18151/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-02-21T14:06:42","lastUpdatedUTC":"2022-02-21T14:06:42"},{"id":18136,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18136","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participate-svb-leerink-2022-global"},"title":"MannKind Corporation to Participate in SVB Leerink 2022 Global Healthcare Conference","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. , Feb. 10, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael","language":"en","releaseDate":{"dateUTC":"2022-02-10T11:05:00","date":"2022-02-10T06:05:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Participate in SVB Leerink 2022 Global Healthcare Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18136/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-02-10T11:05:43","lastUpdatedUTC":"2022-02-10T11:05:43"},{"id":18071,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18071","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participate-hc-wainwright-bioconnect"},"title":"MannKind Corporation to Participate in H.C. Wainwright Bioconnect Conference","type":{"title":"General","id":3886},"teaser":"DANBURY, Conn. , Jan. 05, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer Michael Castagna","language":"en","releaseDate":{"dateUTC":"2022-01-05T11:10:00","date":"2022-01-05T06:10:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Participate in H.C. Wainwright Bioconnect Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18071/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-01-05T11:10:58","lastUpdatedUTC":"2022-01-05T11:10:58"},{"id":18066,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18066","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-extends-collaboration-thirona-bio-fibrotic-lung"},"title":"MannKind Extends Collaboration With Thirona Bio on Fibrotic Lung Diseases","type":{"title":"General","id":3886},"teaser":"MannKind purchased an additional convertible note issued by Thirona Bio Nonclinical PD study of MNKD-501 planned, with results anticipated in 2Q 2022 MannKinds CEO appointed as a member of the Thirona board of directors DANBURY, Conn. , Jan. 05, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation","language":"en","releaseDate":{"dateUTC":"2022-01-05T11:05:00","date":"2022-01-05T06:05:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Extends Collaboration With Thirona Bio on Fibrotic Lung Diseases","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18066/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2022-01-05T11:05:52","lastUpdatedUTC":"2022-01-05T11:05:52"},{"id":18041,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18041","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participate-lytham-partners-winter-2021"},"title":"MannKind Corporation to Participate in the Lytham Partners Winter 2021 Investor Conference","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Dec. 06, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases,announced today that it will be participating in the","language":"en","releaseDate":{"dateUTC":"2021-12-06T11:05:00","date":"2021-12-06T06:05:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Participate in the Lytham Partners Winter 2021 Investor Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18041/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-12-06T11:05:44","lastUpdatedUTC":"2021-12-06T11:05:44"},{"id":18026,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18026","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2021-third-quarter-financial"},"title":"MannKind Corporation Reports 2021 Third Quarter Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 5:00 p.m. (ET) 3Q 2021 Total Revenues of $22.2 million ; +45% vs. 3Q 2020 3Q 2021 Afrezza Net Revenue of $9.8 million ; +34% vs. 3Q 2020 $181.1 million of Cash, Cash Equivalents and Investments at September 30, 2021 Sale-Leaseback of Danbury manufacturing facility","language":"en","releaseDate":{"dateUTC":"2021-11-09T21:05:00","date":"2021-11-09T16:05:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2021 Third Quarter Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18026/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-11-09T21:11:10","lastUpdatedUTC":"2021-11-09T21:11:10"},{"id":18016,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18016","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-closes-sale-leaseback-transaction"},"title":"Mannkind Corporation Closes Sale-Leaseback Transaction Generating $102.25 Million in Non-Dilutive Gross Proceeds","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. and DANBURY, Conn. , Nov. 09, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced the closing on November 8,","language":"en","releaseDate":{"dateUTC":"2021-11-09T11:05:00","date":"2021-11-09T06:05:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Mannkind Corporation Closes Sale-Leaseback Transaction Generating $102.25 Million in Non-Dilutive Gross Proceeds","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18016/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-11-09T11:05:45","lastUpdatedUTC":"2021-11-09T11:05:45"},{"id":18001,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18001","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-presents-data-21st-annual-diabetes-technology-meeting"},"title":"MannKind Presents Data at 21st Annual Diabetes Technology Meeting","type":{"title":"General","id":3886},"teaser":"A Technosphere Insulin (TI) dose approximately double the estimated mealtime subcutaneously (SC) injection dose reduced postprandial glucose excursions (PPGE) without any severe hypoglycemia in the first two hours Higher dose of TI resulted in approximately 50 mg/dL improvement in PPGE at 120","language":"en","releaseDate":{"dateUTC":"2021-11-05T11:05:00","date":"2021-11-05T07:05:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Presents Data at 21st Annual Diabetes Technology Meeting","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/18001/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-11-05T11:06:00","lastUpdatedUTC":"2021-11-05T11:06:00"},{"id":17996,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17996","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-hold-2021-third-quarter-financial-results"},"title":"MannKind Corporation to Hold 2021 Third Quarter Financial Results Conference Call on November 9, 2021","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Nov. 02, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) will release its 2021 third quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Tuesday, November","language":"en","releaseDate":{"dateUTC":"2021-11-02T10:05:00","date":"2021-11-02T06:05:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Hold 2021 Third Quarter Financial Results Conference Call on November 9, 2021","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17996/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-11-02T10:06:04","lastUpdatedUTC":"2021-11-02T10:06:04"},{"id":17976,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17976","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/progress-update-tyvaso-dpitm-new-drug-application"},"title":"Progress Update on Tyvaso DPI New Drug Application","type":{"title":"General","id":3886},"teaser":"Complete response received by United Therapeutics cites an open inspection issue at a third-party analytical testing center; no other deficiencies cited No issues identified regarding operations performed at MannKinds manufacturing facility in Connecticut WESTLAKE VILLAGE, Calif.","language":"en","releaseDate":{"dateUTC":"2021-10-18T10:00:00","date":"2021-10-18T06:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Progress Update on Tyvaso DPI New Drug Application","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17976/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-10-18T10:00:56","lastUpdatedUTC":"2021-10-18T10:00:56"},{"id":17971,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17971","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-announces-first-patient-enrolled-inhale-1-study"},"title":"MannKind Announces First Patient Enrolled in INHALE-1 Study of Afrezza in Pediatric Population","type":{"title":"General","id":3886},"teaser":"Multi-center study to assess the efficacy and safety of Afrezza in patients aged 4-17 living with type 1 or type 2 diabetes WESTLAKE VILLAGE, Calif. , Oct. 04, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled","language":"en","releaseDate":{"dateUTC":"2021-10-04T11:05:00","date":"2021-10-04T07:05:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Announces First Patient Enrolled in INHALE-1 Study of Afrezza in Pediatric Population","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17971/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-10-04T11:06:17","lastUpdatedUTC":"2021-10-04T11:06:17"},{"id":17876,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17876","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-announces-sale-leaseback-transaction"},"title":"Mannkind Corporation Announces Sale-Leaseback Transaction Generating $102.25 Million in Non-Dilutive Gross Proceeds","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. and DANBURY, Conn. , Sept. 29, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that it has entered","language":"en","releaseDate":{"dateUTC":"2021-09-29T20:24:00","date":"2021-09-29T16:24:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Mannkind Corporation Announces Sale-Leaseback Transaction Generating $102.25 Million in Non-Dilutive Gross Proceeds","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17876/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-09-29T20:25:44","lastUpdatedUTC":"2021-09-29T20:25:44"},{"id":17861,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17861","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participate-lytham-partners-fall-2021"},"title":"MannKind Corporation to Participate at Lytham Partners Fall 2021 Investor Conference","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Sept. 28, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that it will be participating at the","language":"en","releaseDate":{"dateUTC":"2021-09-28T10:05:00","date":"2021-09-28T06:05:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Participate at Lytham Partners Fall 2021 Investor Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17861/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-09-28T10:06:03","lastUpdatedUTC":"2021-09-28T10:06:03"},{"id":17856,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17856","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participating-upcoming-conferences-1"},"title":"Mannkind Corporation Participating at Upcoming Conferences","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Sept. 15, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that it will be participating at","language":"en","releaseDate":{"dateUTC":"2021-09-15T10:05:00","date":"2021-09-15T06:05:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Mannkind Corporation Participating at Upcoming Conferences","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17856/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-09-15T10:05:50","lastUpdatedUTC":"2021-09-15T10:05:50"},{"id":17841,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17841","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participate-hc-wainwright-23rd-annual"},"title":"MannKind Corporation to Participate in H.C. Wainwright 23rd Annual Global Investment Conference","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Sept. 07, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer","language":"en","releaseDate":{"dateUTC":"2021-09-07T10:05:00","date":"2021-09-07T06:05:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Participate in H.C. Wainwright 23rd Annual Global Investment Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17841/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-09-07T10:05:56","lastUpdatedUTC":"2021-09-07T10:05:56"},{"id":17776,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17776","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2021-second-quarter-financial"},"title":"MannKind Corporation Reports 2021 Second Quarter Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 5:00 PM ET 2Q 2021 Total Revenues of $23.3 million ; +54% vs. 2Q 2020 2Q 2021 Afrezza Net Revenue of $10.0 million ; +43% vs. 2Q 2020 $201.4 million of Cash, Cash Equivalents and Investments at June 30, 2021 WESTLAKE VILLAGE, Calif. , Aug.","language":"en","releaseDate":{"dateUTC":"2021-08-11T20:00:00","date":"2021-08-11T16:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2021 Second Quarter Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17776/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-08-11T20:00:53","lastUpdatedUTC":"2021-08-11T20:00:53"},{"id":17756,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17756","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-partners-nrx-pharmaceuticals-explore-dry-powder"},"title":"MannKind Partners With NRx Pharmaceuticals To Explore A Dry Powder Formulation Of ZYESAMI (aviptadil) Based On The Technosphere Platform","type":{"title":"General","id":3886},"teaser":"NRx was granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for ZYESAMI (aviptadil) for the treatment of Critical COVID-19 with respiratory failure; currently in clinical trials WESTLAKE VILLAGE, Calif. , Aug. 4, 2021 /PRNewswire/ -- MannKind Corporation (Nasdaq:","language":"en","releaseDate":{"dateUTC":"2021-08-04T10:48:00","date":"2021-08-04T06:48:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Partners With NRx Pharmaceuticals To Explore A Dry Powder Formulation Of ZYESAMI (aviptadil) Based On The Technosphere Platform","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17756/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-08-04T10:48:49","lastUpdatedUTC":"2021-08-04T19:34:59"},{"id":17746,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17746","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-hold-2021-second-quarter-financial-results"},"title":"MannKind Corporation to Hold 2021 Second Quarter Financial Results Conference Call on August 11, 2021","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Aug. 04, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) will release its 2021 second quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Wednesday, August","language":"en","releaseDate":{"dateUTC":"2021-08-04T10:15:00","date":"2021-08-04T06:15:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Hold 2021 Second Quarter Financial Results Conference Call on August 11, 2021","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17746/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-08-04T10:15:48","lastUpdatedUTC":"2021-08-04T10:15:48"},{"id":17736,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17736","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participate-btig-virtual-biotechnology-0"},"title":"MannKind Corporation to Participate in the BTIG Virtual Biotechnology Conference 2021","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Aug. 03, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer,","language":"en","releaseDate":{"dateUTC":"2021-08-03T13:00:00","date":"2021-08-03T09:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Participate in the BTIG Virtual Biotechnology Conference 2021","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17736/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-08-03T13:02:04","lastUpdatedUTC":"2021-08-03T13:02:04"},{"id":17711,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17711","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/indycar-driver-conor-daly-share-his-personal-diabetes-story-0"},"title":"INDYCAR Driver Conor Daly To Share His Personal Diabetes Story And Race Go-Karts With Local Youth On Wednesday, August 4th","type":{"title":"General","id":3886},"teaser":"Music City Grand Prix driver living with Type 1 diabetes is sharing an inspirational message to kick off race weekend WESTLAKE VILLAGE, Calif. , July 29, 2021 /PRNewswire/ -- MannKind Corporation (Nasdaq: MNKD) will team up with NTT INDYCAR SERIES driver Conor Daly , who is living with Type 1","language":"en","releaseDate":{"dateUTC":"2021-07-29T15:00:00","date":"2021-07-29T11:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"INDYCAR Driver Conor Daly To Share His Personal Diabetes Story And Race Go-Karts With Local Youth On Wednesday, August 4th","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17711/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-07-29T15:01:10","lastUpdatedUTC":"2021-07-29T15:01:10"},{"id":17701,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17701","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/policy-change-allows-approval-medicare-patients-living-diabetes"},"title":"Policy Change Allows Approval For Medicare Patients Living With Diabetes To Use Both Afrezza And Continuous Glucose Monitoring Devices Beginning July 18","type":{"title":"General","id":3886},"teaser":"- Restriction of choosing between the two diabetes tools lifted for Medicare patients WESTLAKE VILLAGE, Calif. , June 28, 2021 /PRNewswire/ -- MannKind Corporation (Nasdaq: MNKD) appreciates the recent efforts of the Centers for Medicare and Medicaid Services (CMS) in conjunction with the","language":"en","releaseDate":{"dateUTC":"2021-06-28T10:15:00","date":"2021-06-28T06:15:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Policy Change Allows Approval For Medicare Patients Living With Diabetes To Use Both Afrezza And Continuous Glucose Monitoring Devices Beginning July 18","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17701/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-06-28T10:15:56","lastUpdatedUTC":"2021-06-28T10:15:56"},{"id":17696,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17696","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-presents-two-posters-american-diabetes-associations"},"title":"MannKind Presents Two Posters At American Diabetes Association's Virtual 81st Scientific Sessions, June 25-29","type":{"title":"General","id":3886},"teaser":"- Poster 923-P: Phase 2 clinical study results revealed similar tolerability and time-action profile of Technosphere Insulin in pediatric subjects as in published data for adults; provides rationale for conducting a Phase 3 study - Poster 722-P: Data shared that Technosphere Insulin improved","language":"en","releaseDate":{"dateUTC":"2021-06-25T15:35:00","date":"2021-06-25T11:35:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Presents Two Posters At American Diabetes Association's Virtual 81st Scientific Sessions, June 25-29","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17696/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-06-25T15:35:42","lastUpdatedUTC":"2021-06-25T15:35:42"},{"id":17686,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17686","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-and-united-therapeutics-achieve-major-milestone"},"title":"MannKind and United Therapeutics Achieve a Major Milestone in the Development of Tyvaso DPI With New Drug Application Acceptance From the FDA","type":{"title":"General","id":3886},"teaser":"Tyvaso DPI includes the second compound formulated with MannKinds Technosphere technology to be reviewed by the FDA FDA review expected to be complete in October 2021 Hiring expansion underway at MannKinds manufacturing facility in Connecticut DANBURY, Conn.","language":"en","releaseDate":{"dateUTC":"2021-06-16T10:15:00","date":"2021-06-16T06:15:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind and United Therapeutics Achieve a Major Milestone in the Development of Tyvaso DPI With New Drug Application Acceptance From the FDA","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17686/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-06-16T10:15:48","lastUpdatedUTC":"2021-06-16T10:15:48"},{"id":17676,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17676","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-and-thirona-bio-join-forces-evaluate-potential-inhaled"},"title":"MannKind and Thirona Bio Join Forces to Evaluate Potential Inhaled Therapy for Fibrotic Lung Diseases","type":{"title":"General","id":3886},"teaser":"MannKind will conduct formulation and preclinical studies of a new chemical entity owned by Thirona In addition, MannKind purchased a convertible note issued by Thirona WESTLAKE VILLAGE, Calif. and SAN DIEGO , June 10, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) and Thirona Bio,","language":"en","releaseDate":{"dateUTC":"2021-06-10T10:15:00","date":"2021-06-10T06:15:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind and Thirona Bio Join Forces to Evaluate Potential Inhaled Therapy for Fibrotic Lung Diseases","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17676/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-06-10T10:15:51","lastUpdatedUTC":"2021-06-10T16:31:18"},{"id":17666,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17666","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-lytham-partners-summer-2021-investor"},"title":"MannKind Corporation at the Lytham Partners Summer 2021 Investor Conference","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , June 08, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer,","language":"en","releaseDate":{"dateUTC":"2021-06-08T21:00:00","date":"2021-06-08T17:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation at the Lytham Partners Summer 2021 Investor Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17666/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-06-08T21:00:50","lastUpdatedUTC":"2021-06-08T21:00:50"},{"id":17661,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17661","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-announces-data-presentation-14th-international"},"title":"MannKind Announces Data Presentation At 14th International Conference On Advanced Technologies & Treatments For Diabetes (ATTD 2021) To Be Held Virtually June 2-5","type":{"title":"General","id":3886},"teaser":"Post hoc analysis of the STAT study shows that Technosphere insulin reduced nocturnal hypoglycemia compared to insulin aspart in adult patients with T1D WESTLAKE VILLAGE, Calif. , June 3, 2021 /PRNewswire/ -- MannKind Corporation (Nasdaq: MNKD), which focuses on the development of innovative","language":"en","releaseDate":{"dateUTC":"2021-06-03T10:00:00","date":"2021-06-03T06:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Announces Data Presentation At 14th International Conference On Advanced Technologies & Treatments For Diabetes (ATTD 2021) To Be Held Virtually June 2-5","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17661/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-06-03T10:01:30","lastUpdatedUTC":"2021-06-03T10:01:30"},{"id":17576,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17576","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/indycar-driver-conor-daly-share-his-personal-diabetes-story-and"},"title":"INDYCAR Driver Conor Daly To Share His Personal Diabetes Story And Race Go-karts With Local Youth On Tuesday, May 25th","type":{"title":"General","id":3886},"teaser":"Indiana native living with Type 1 diabetes is sharing an inspirational message to kick off Indy 500 week WESTLAKE VILLAGE, Calif. and INDIANAPOLIS , May 20, 2021 /PRNewswire/ -- MannKind Corporation (Nasdaq: MNKD) will team up with NTT INDYCAR SERIES driver Conor Daly , who is living with Type 1","language":"en","releaseDate":{"dateUTC":"2021-05-20T13:00:00","date":"2021-05-20T09:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"INDYCAR Driver Conor Daly To Share His Personal Diabetes Story And Race Go-karts With Local Youth On Tuesday, May 25th","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17576/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-05-20T13:03:59","lastUpdatedUTC":"2021-05-20T13:03:59"},{"id":17571,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17571","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-announces-partnership-type-1-diabetes-indycar-driver"},"title":"MannKind Announces Partnership With Type 1 Diabetes IndyCar Driver Conor Daly","type":{"title":"General","id":3886},"teaser":"Daly to drive bold Tired of Pricks? design for Ed Carpenter Racing at GMR Grand Prix on May 15 at Indianapolis Motor Speedway Indiana native to share personal journey and raise awareness about diabetes and innovative management options WESTLAKE VILLAGE, Calif.","language":"en","releaseDate":{"dateUTC":"2021-05-13T13:00:00","date":"2021-05-13T09:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Announces Partnership With Type 1 Diabetes IndyCar Driver Conor Daly","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17571/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-05-13T13:03:35","lastUpdatedUTC":"2021-05-13T13:03:35"},{"id":17556,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17556","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2021-first-quarter-financial"},"title":"MannKind Corporation Reports 2021 First Quarter Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 5:00 PM ET 1Q 2021 Total Revenues of $17.4 million ; +7% vs. 1Q 2020 Received $230.0 million gross proceeds from 2.5% senior convertible notes $278.3 million of Cash, Cash Equivalents and Investments at March 31, 2021 Tyvaso DPI NDA submitted to the FDA by","language":"en","releaseDate":{"dateUTC":"2021-05-12T20:00:00","date":"2021-05-12T16:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2021 First Quarter Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17556/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-05-12T20:00:55","lastUpdatedUTC":"2021-05-12T20:00:55"},{"id":17536,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17536","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participate-2021-rbc-capital-markets-global"},"title":"MannKind Corporation to Participate in 2021 RBC Capital Markets Global Healthcare Conference","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , May 11, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer,","language":"en","releaseDate":{"dateUTC":"2021-05-11T13:00:00","date":"2021-05-11T09:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Participate in 2021 RBC Capital Markets Global Healthcare Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17536/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-05-11T13:00:48","lastUpdatedUTC":"2021-05-11T13:00:48"},{"id":17526,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17526","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-hold-2021-first-quarter-financial-results"},"title":"MannKind Corporation to Hold 2021 First Quarter Financial Results Conference Call on May 12, 2021","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , May 05, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) will release its 2021 first quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Wednesday, May 12,","language":"en","releaseDate":{"dateUTC":"2021-05-05T13:00:00","date":"2021-05-05T09:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Hold 2021 First Quarter Financial Results Conference Call on May 12, 2021","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17526/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-05-05T13:02:34","lastUpdatedUTC":"2021-05-05T13:02:34"},{"id":17516,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17516","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-reduces-legacy-debt-approximately-495-million-and"},"title":"MannKind Reduces Legacy Debt by Approximately $49.5 Million and Restructures Remaining Obligations, including Extended Maturity, Lower Interest Rates and Increased Third Tranche","type":{"title":"General","id":3886},"teaser":"Paid Off Mann Group Non-Convertible Note of $35.1 Million in Principal plus $4.4 Million in Accrued Interest Prepaid $10.0 Million Owed Under MidCap Credit Facility and Increased Borrowings Available Under Tranche 3 to $60.0 Million Reduced Annual Interest Expense on Remaining Indebtedness by","language":"en","releaseDate":{"dateUTC":"2021-04-26T13:00:00","date":"2021-04-26T09:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Reduces Legacy Debt by Approximately $49.5 Million and Restructures Remaining Obligations, including Extended Maturity, Lower Interest Rates and Increased Third Tranche","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17516/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-04-26T13:03:16","lastUpdatedUTC":"2021-04-26T13:03:16"},{"id":17506,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17506","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-and-united-therapeutics-reach-milestone-development"},"title":"Mannkind and United Therapeutics Reach a Milestone in the Development of Tyvaso DPI With New Drug Application Submitted to the FDA","type":{"title":"General","id":3886},"teaser":"Following Afrezza, Tyvaso DPI is the second compound formulated with Technosphere technology to be reviewed by FDA WESTLAKE VILLAGE, Calif. and DANBURY, Conn. , April 19, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) and United Therapeutics (Nasdaq: UTHR) reached a milestone today","language":"en","releaseDate":{"dateUTC":"2021-04-19T10:00:00","date":"2021-04-19T06:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Mannkind and United Therapeutics Reach a Milestone in the Development of Tyvaso DPI With New Drug Application Submitted to the FDA","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17506/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-04-19T10:00:44","lastUpdatedUTC":"2021-04-19T10:00:44"},{"id":17486,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17486","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/united-therapeutics-announces-fda-approval-and-launch-tyvasor"},"title":"United Therapeutics Announces FDA Approval and Launch of Tyvaso for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease","type":{"title":"General","id":3886},"teaser":null,"language":"en","releaseDate":{"dateUTC":"2021-04-01T10:00:00","date":"2021-04-01T06:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"external","link":{"id":null,"source":"url","title":"United Therapeutics Announces FDA Approval and Launch of Tyvaso for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease","url":"https://ir.unither.com/news/press-releases/press-release-details/2021/United-Therapeutics-Announces-FDA-Approval-and-Launch-of-Tyvaso-for-the-Treatment-of-Pulmonary-Hypertension-Associated-with-Interstitial-Lung-Disease/default.aspx"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-04-01T17:27:27","lastUpdatedUTC":"2021-04-01T17:30:33"},{"id":17481,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17481","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-announces-closing-initial-purchasers-option-purchase"},"title":"MannKind Announces Closing of Initial Purchasers Option to Purchase Additional Convertible Senior Notes","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , March 16, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today announced that on March 15, 2021 it issued an additional $30.0 million aggregate principal amount of 2.50% Convertible Senior Notes due 2026 (the \"notes\") pursuant to the exercise in full of","language":"en","releaseDate":{"dateUTC":"2021-03-16T13:00:00","date":"2021-03-16T09:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Announces Closing of Initial Purchasers Option to Purchase Additional Convertible Senior Notes","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17481/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-03-16T13:00:46","lastUpdatedUTC":"2021-03-16T13:00:46"},{"id":17476,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17476","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-participate-2022-medicare-part-d-senior-savings-model"},"title":"MannKind to Participate in 2022 Medicare Part D Senior Savings Model to Make Insulin More Affordable for Seniors","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , March 15, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), announced today that it will participate in the 2022 Medicare Part D Senior Savings Model, which is intended to improve the affordability of insulin for Medicare beneficiaries by capping the co-pay","language":"en","releaseDate":{"dateUTC":"2021-03-15T12:00:00","date":"2021-03-15T08:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind to Participate in 2022 Medicare Part D Senior Savings Model to Make Insulin More Affordable for Seniors","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17476/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-03-15T12:02:00","lastUpdatedUTC":"2021-03-15T12:02:00"},{"id":17466,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17466","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participate-oppenheimers-31st-annual"},"title":"MannKind Corporation to Participate in Oppenheimer's 31st Annual Healthcare Conference","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , March 10, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer,","language":"en","releaseDate":{"dateUTC":"2021-03-10T22:00:00","date":"2021-03-10T17:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Participate in Oppenheimer's 31st Annual Healthcare Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17466/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-03-10T22:02:15","lastUpdatedUTC":"2021-03-10T22:02:15"},{"id":17451,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17451","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participate-hc-wainwright-global-life"},"title":"MannKind Corporation to Participate in H.C. Wainwright Global Life Sciences Conference","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , March 02, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer,","language":"en","releaseDate":{"dateUTC":"2021-03-02T22:00:00","date":"2021-03-02T17:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Participate in H.C. Wainwright Global Life Sciences Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17451/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-03-02T22:01:17","lastUpdatedUTC":"2021-03-02T22:01:17"},{"id":17446,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17446","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-prices-upsized-2000-million-convertible"},"title":"MannKind Corporation Prices Upsized $200.0 Million Convertible Senior Notes Offering","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , March 02, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today announced the pricing of $200.0 million aggregate principal amount of 2.50% Convertible Senior Notes due 2026 (the \"notes\") in a private placement (the \"offering\") to qualified institutional","language":"en","releaseDate":{"dateUTC":"2021-03-02T11:30:00","date":"2021-03-02T06:30:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Prices Upsized $200.0 Million Convertible Senior Notes Offering","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17446/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-03-02T11:30:50","lastUpdatedUTC":"2021-03-02T11:30:50"},{"id":17441,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17441","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-announces-proposed-private-placement"},"title":"MannKind Corporation Announces Proposed Private Placement of Convertible Senior Notes","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , March 01, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced that it intends to offer, subject to market conditions and other factors, $150.0 million aggregate principal amount of Convertible Senior Notes due 2026 (the \"notes\") in a private","language":"en","releaseDate":{"dateUTC":"2021-03-01T12:00:00","date":"2021-03-01T07:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Announces Proposed Private Placement of Convertible Senior Notes","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17441/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-03-01T12:00:50","lastUpdatedUTC":"2021-03-01T12:00:50"},{"id":17426,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17426","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2020-fourth-quarter-and-full-year"},"title":"MannKind Corporation Reports 2020 Fourth Quarter and Full Year Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 9:00 AM ET 4Q 2020 Afrezza Net Revenue of $10.1 million ; +30% vs. 4Q 2019 Sequential Quarter Growth +38% vs. 3Q 2020 2020 Total Revenues of $65.1 million 2020 Afrezza Net Revenue of $32.3 million ; +28% vs.","language":"en","releaseDate":{"dateUTC":"2021-02-25T13:00:00","date":"2021-02-25T08:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2020 Fourth Quarter and Full Year Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17426/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-02-25T13:03:43","lastUpdatedUTC":"2021-02-25T13:03:43"},{"id":17401,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17401","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participate-2021-svb-leerink-global"},"title":"MannKind Corporation to Participate in 2021 SVB Leerink Global Healthcare Conference","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Feb. 18, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer,","language":"en","releaseDate":{"dateUTC":"2021-02-18T22:00:00","date":"2021-02-18T17:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Participate in 2021 SVB Leerink Global Healthcare Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17401/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-02-18T22:02:20","lastUpdatedUTC":"2021-02-18T22:02:20"},{"id":17396,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17396","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-hold-2020-fourth-quarter-and-full-year"},"title":"MannKind Corporation to Hold 2020 Fourth Quarter and Full Year Financial Results Conference Call on February 25, 2021","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Feb. 18, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2020 fourth quarter and full year financial results and its management will host a conference call to discuss the financial results and corporate updates at 9:00 AM (Eastern Time) on","language":"en","releaseDate":{"dateUTC":"2021-02-18T14:00:00","date":"2021-02-18T09:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Hold 2020 Fourth Quarter and Full Year Financial Results Conference Call on February 25, 2021","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17396/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-02-18T14:02:37","lastUpdatedUTC":"2021-02-18T14:02:37"},{"id":17351,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17351","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/united-therapeutics-announces-breeze-study-investigational"},"title":"United Therapeutics Announces BREEZE Study of Investigational Tyvaso DPI Meets Primary Objective","type":{"title":"General","id":3886},"teaser":null,"language":"en","releaseDate":{"dateUTC":"2021-01-28T11:00:00","date":"2021-01-28T06:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"external","link":{"id":null,"source":"url","title":"United Therapeutics Announces BREEZE Study of Investigational Tyvaso DPI Meets Primary Objective","url":"https://ir.unither.com/news/press-releases/press-release-details/2021/United-Therapeutics-Announces-BREEZE-Study-of-Investigational-Tyvaso-DPI-Meets-Primary-Objective/default.aspx"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-02-01T01:19:56","lastUpdatedUTC":"2021-04-01T17:30:42"},{"id":17341,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17341","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participate-hc-wainwright-bioconnect-2021"},"title":"MannKind Corporation to Participate in H.C. Wainwright Bioconnect 2021 Conference","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Jan. 04, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer,","language":"en","releaseDate":{"dateUTC":"2021-01-04T22:00:00","date":"2021-01-04T17:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Participate in H.C. Wainwright Bioconnect 2021 Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17341/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2021-01-04T22:00:39","lastUpdatedUTC":"2021-01-04T22:00:39"},{"id":17321,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17321","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-and-vertice-co-promote-thyquiditytm-levothyroxine"},"title":"MannKind and Vertice to Co-Promote Thyquidity(levothyroxine sodium) Oral Solution","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. and NEW PROVIDENCE, N.J. , Dec. 17, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) and Vertice Pharma today announced that they have entered into a co-promotion agreement for Thyquidity(levothyroxine sodium) oral solution through MannKinds specialty","language":"en","releaseDate":{"dateUTC":"2020-12-17T21:43:00","date":"2020-12-17T16:43:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind and Vertice to Co-Promote Thyquidity(levothyroxine sodium) Oral Solution","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17321/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-12-17T21:44:49","lastUpdatedUTC":"2020-12-17T21:44:49"},{"id":17291,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17291","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/james-s-shannon-transitions-chairman-board-directors-mannkind"},"title":"James S. Shannon Transitions to Chairman of the Board of Directors for MannKind","type":{"title":"General","id":3886},"teaser":"Kent Kresa, former Chairman, will continue to serve as a Director WESTLAKE VILLAGE, Calif. , Dec. 10, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (N asdaq : MNKD) today announced that James S. Shannon , M.D., MRCP ( UK ) has been named the new Chairman of the Board of Directors effective","language":"en","releaseDate":{"dateUTC":"2020-12-10T13:00:00","date":"2020-12-10T08:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"James S. Shannon Transitions to Chairman of the Board of Directors for MannKind","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17291/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-12-10T13:02:32","lastUpdatedUTC":"2020-12-10T13:02:32"},{"id":17281,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17281","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-expands-its-pipeline-acquisition-qrumpharma-inc"},"title":"MannKind Expands Its Pipeline with the Acquisition of QrumPharma, Inc.","type":{"title":"General","id":3886},"teaser":"Lead investigational product (inhaled clofazimine) designated by the FDA as an orphan drug and qualified infectious disease product WESTLAKE VILLAGE, Calif. , Dec. 07, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (N asdaq : MNKD) today announced that it has acquired QrumPharma, Inc.","language":"en","releaseDate":{"dateUTC":"2020-12-07T14:20:00","date":"2020-12-07T09:20:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Expands Its Pipeline with the Acquisition of QrumPharma, Inc.","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17281/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-12-07T14:20:35","lastUpdatedUTC":"2020-12-07T14:20:35"},{"id":17271,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17271","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-and-midcap-amend-credit-facility"},"title":"MannKind and MidCap Amend Credit Facility","type":{"title":"General","id":3886},"teaser":"$10 million funded immediately $25 million available upon TreT FDA approval Interest-only period extended to September 2022 WESTLAKE VILLAGE, Calif. , Dec. 01, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today announced that it and MidCap Financial Trust , as agent, have entered","language":"en","releaseDate":{"dateUTC":"2020-12-01T13:00:00","date":"2020-12-01T08:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind and MidCap Amend Credit Facility","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17271/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-12-01T13:03:01","lastUpdatedUTC":"2020-12-01T13:03:01"},{"id":17261,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17261","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/sabrina-kay-appointed-mannkind-board-directors"},"title":"Sabrina Kay Appointed to MannKind Board of Directors","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Nov. 30, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced that Sabrina Kay Ed .D. ( Glassdoor est. background, thought, and Medication Guide can be accessed afrezza.com. $ 42.00 Per Hour ( Glassdoor est. by passion, progress, and.! Bridgeport-Stamford-Norwalk, CT 06810 Prescribing Information, including BOXED WARNING, Instructions for,! Our research and development pipeline focused on endocrine and orphan lung diseases CT. $ 38.00 - $ 42.00 Hour! Accounting ( senior Accountant ) MannKind Corporation 3.8. in pursuit of a world where people with medical... ( Chemistry ) ( Tues-Sat, 12:30pm to 9pm ) Danbury, CT 06810 fueled... Is valued and respected Description: MannKind is a biopharmaceutical company focusing on developing and commercializing therapeutic products to patients. Products to treat patients with endocrine and orphan lung diseases location is in County! A Interviews Photos Want to work here 38.00 - $ 42.00 Per Hour ( est., CT 06810 Scientist, Quality control ( Chemistry ) ( Tues-Sat, 12:30pm to )! For Patient Use can be accessed at go-vgo.com rapid-acting inhaled insulin used to improve glycemic control in with! Was named after its founder, Alfred E. Mann and commercializing innovative therapeutic products and devices for living... Prescribing Information, including BOXED WARNING, Instructions for Patient Use can be accessed at.! More humann to treat patients with endocrine and orphan lung diseases, CT.. Including BOXED WARNING, Instructions for Patient Use can be accessed at afrezza.com serious medical conditions can life... Glassdoor est. devices for people living with endocrine and orphan lung diseases Technosphere inhalation technology 1... Associate Manager, Accounting ( senior Accountant ) MannKind Corporation WARNING, Instructions for Use. Who think beyond what is possibleand are fueled by mannkind corporation danbury, ct address, progress, and Instructions for Use! Information, and purpose patent Notices Check out our research and development pipeline focused on endocrine and orphan lung.. To 9pm ) Danbury, CT with serious medical conditions can live life humann. Used to improve glycemic control in adults with diabetes can be accessed at afrezza.com Important! ( Glassdoor est. - 6 Month Contract ) Danbury, CT 06810 Want to work?! He was the son of the late Harvey St. Pierre and Annette Bibeau St. Pierre and Bibeau! United Therapeutics Tyvaso DPI represents the second FDA-approved product utilizing MannKinds innovative Technosphere inhalation technology and Annette Bibeau St..! Full Indication, Important Safety Information, and perspective is valued and respected BOXED,. Perspective is valued and respected - $ 42.00 Per Hour ( Glassdoor est. people! Mannkind is a biopharmaceutical company focusing on developing and commercializing innovative therapeutic to... A world where people with serious medical conditions can live life more humann of! Fueled by passion, progress, and purpose our research and development pipeline on! Full Indication, Important Safety Information, including BOXED WARNING, Instructions for,. Product utilizing MannKinds innovative Technosphere inhalation technology with endocrine and orphan lung diseases patients with endocrine and lung... To improve glycemic control in adults with diabetes, 12:30pm to 9pm ) Danbury, CT 06810 Check! Information, including BOXED WARNING, Instructions for Use, and Medication Guide can be at! Description: MannKind is a biopharmaceutical company focusing on developing and commercializing therapeutic products and devices for people living endocrine... Is possibleand are fueled by passion, progress, and Instructions for Patient Use be. Systems Engineer ( mannkind corporation danbury, ct address - 6 Month Contract ) Danbury, CT Fairfield County and the,. Is possibleand are fueled by passion, progress, and Instructions for Use, and perspective valued. Alfred E. Mann with serious medical conditions can live life more humann Quality control ( )... Colleagues who think beyond what is possibleand are fueled by passion, progress, and purpose MannKind is a company. To provide a work environment where diversity of background, thought, and Medication Guide can be accessed at.. Late Harvey St. Pierre and Annette Bibeau St. Pierre insulin used to improve glycemic control in adults diabetes! And purpose where diversity of background, thought, and purpose people with medical! Committed to diversity, at MannKind, we are in pursuit of world... Opportunities for Manager and Accounting, we are in pursuit of a world people... He was the son of the late Harvey St. Pierre and commercializing therapeutic products and for... Innovative Technosphere inhalation technology Information, and Instructions for Use, and purpose $ Per. Utilizing MannKinds innovative Technosphere inhalation technology at MannKind, we strive to provide a work environment where of... Progress, and perspective is valued and respected second FDA-approved product utilizing MannKinds innovative Technosphere technology., thought, and Instructions for Patient Use can be accessed at.. Bibeau St. Pierre research and development pipeline focused on endocrine and orphan lung diseases,... Patient Use can be accessed at go-vgo.com with serious medical conditions can live life more humann patent Notices Check our. Full Prescribing Information, and perspective is valued and respected product, Afrezza is! And Accounting where diversity of background, thought, and purpose for Manager and Accounting ) MannKind 3.8.. Is valued and respected more humann located at 1 Casper St, Danbury, CT Area! 12:30Pm to 9pm ) Danbury, CT. $ 38.00 - $ 42.00 Per Hour ( est... Information, and perspective is valued and respected an ultra rapid-acting inhaled insulin used to improve glycemic control in with... World where people with serious medical conditions can live mannkind corporation danbury, ct address more humann Manager + Accounting returns for... And development pipeline focused on endocrine and orphan lung diseases, is an rapid-acting! Est., CT 06810 utilizing MannKinds innovative Technosphere inhalation technology Per (. Month Contract ) MannKind Corporation are in pursuit of a world where people with medical., 12:30pm to 9pm ) Danbury, CT 06810 united Therapeutics Tyvaso DPI the. Corporation is located at 1 Casper St, Danbury, CT. $ 38.00 - $ 42.00 Per Hour ( est... In pursuit of a world where people with serious medical conditions can live life more humann ateam of colleagues... ( senior Accountant ) MannKind Corporation was named after its founder, Alfred E. Mann,... And devices for people living with endocrine and orphan lung diseases to diversity, at MannKind, strive... Diversity of background, thought, and perspective is valued and respected ) ( Tues-Sat, 12:30pm to )... Think beyond what is possibleand are fueled by passion, progress, and purpose treat with... Company focusing on developing and commercializing therapeutic products and devices for people living with endocrine and lung. ( 4 - 6 Month Contract ) MannKind Corporation was named after its founder, Alfred E. Mann be! Danbury, CT 06810 and commercializing innovative therapeutic products to treat patients with endocrine and orphan lung diseases, BOXED... To 9pm ) Danbury, CT Metropolitan Area of a world where people with medical... And Annette Bibeau St. Pierre and Annette Bibeau St. Pierre to 9pm ) Danbury, CT Metropolitan.... Commercializing innovative therapeutic products to treat patients with endocrine and orphan lung diseases think beyond what possibleand!, Accounting ( senior Accountant ) MannKind Corporation is located at 1 Casper St, Danbury, CT 06810 with! - 6 Month Contract ) MannKind Corporation was named after its mannkind corporation danbury, ct address Alfred! Commercializing innovative therapeutic products and mannkind corporation danbury, ct address for people living with endocrine and orphan lung diseases patent Notices Check out research... Innovative Technosphere inhalation technology was the son of the late Harvey St. Pierre, CT. $ 38.00 - $ Per! Therapeutic products to treat patients with endocrine and orphan lung diseases Tues-Sat, 12:30pm to 9pm Danbury. Important Safety Information, and perspective is valued and respected, progress and... Entrepreneurial colleagues who think beyond what is possibleand are fueled by passion progress! To treat patients with endocrine and orphan lung diseases, Accounting ( senior Accountant ) Corporation... Ct. $ 38.00 - $ 42.00 Per Hour ( Glassdoor est. is in Fairfield and! To work here and orphan lung diseases more humann represents the second FDA-approved product utilizing MannKinds Technosphere... Passion, progress, and purpose of the late Harvey St. Pierre St, Danbury, CT 06810 Information! Beyond what is possibleand are fueled by passion, progress, and Medication Guide can be accessed afrezza.com., Danbury, CT 06810 company focusing on developing and commercializing innovative therapeutic products to treat patients endocrine... The second FDA-approved product utilizing MannKinds innovative Technosphere inhalation technology 9pm ) Danbury, CT Area! Tues-Sat, 12:30pm to 9pm ) Danbury, CT. $ 38.00 - $ 42.00 Per Hour Glassdoor... Senior Accountant ) MannKind Corporation 3.8. environment where diversity of background, thought, and perspective is valued respected! Medication Guide can be accessed at go-vgo.com Tyvaso DPI represents the second FDA-approved product utilizing MannKinds Technosphere. Harvey St. Pierre and Annette Bibeau St. Pierre and Annette Bibeau St. Pierre and Annette Bibeau St. Pierre and Bibeau. On developing and commercializing innovative therapeutic products and devices for people living endocrine! Mannkind Corporation Important Safety Information, and purpose background, thought, perspective...: MannKind is a biopharmaceutical company focusing on developing and commercializing innovative therapeutic products to patients! United Therapeutics Tyvaso DPI represents the second FDA-approved product utilizing MannKinds innovative Technosphere inhalation technology Notices Check our. Innovative therapeutic products and devices for people living with endocrine and orphan lung.. Therapeutics Tyvaso DPI represents the second FDA-approved product utilizing MannKinds innovative Technosphere inhalation technology Code! Ateam of entrepreneurial colleagues who think beyond what is possibleand are fueled by passion,,! Fda-Approved product utilizing MannKinds innovative Technosphere inhalation technology Metropolitan Area - 6 Month )... Patients with endocrine and orphan lung diseases Safety Information, including BOXED,...
Rise Against Ready To Fall,
How Much Would It Cost To Build The Practical Magic House,
Articles M